ERBB2 and breast neoplasm: In a short-term study of a double-blind and randomized phase III trial (NCT01479244) involving patients with LN + and low HER2 + breast tumors, an interim study did not reveal any difference in disease-free survival between E75-vaccinated and placebo-vaccinated patients [202].